Video Hero Poster

Partner of choice in specialty, hospital, and rare disease medicines

Learn More

ADVANZ PHARMA is a global pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals. We are committed to improving patients' lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on.

Since the acquisition of the majority of Intercept Pharmaceuticals’ subsidiaries and operations in Europe, Canada, and all other markets outside of the U.S., ADVANZ PHARMA has a sizable presence in the treatment of rare diseases with Ocaliva® as an orphan drug in PBC (a progressive autoimmune disease affecting the liver).

Our portfolio of specialty, hospital, and rare disease medicines focuses on Hepatology, Gastroenterology, Anti-infectives, Endocrinology and Critical Care medicines with the ambition to make a meaningful difference for patients.

We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values Entrepreneurship, Speed, and Integrity.

Our portfolio —

At ADVANZ PHARMA, we serve patients with specialty, hospital, and rare disease medicines with a focus on Hepatology, Gastroenterology, Anti-infectives, Endocrinology and Critical Care.

We have a broad portfolio of overall more than 180 brands, and we bring our medicines to patients in over 80 countries.

Careers & Culture —

The success of any company is driven by its people, and we are no different. We aim to be the best team in the industry by embracing challenges and change. We live our company values Entrepreneurship, Speed, and Integrity.

Responsibility —

ADVANZ PHARMA is committed to bringing important medicines to even more patients across the globe and to improving the lives of patients by providing and enhancing the specialty and hospital medicines they depend on.

Our Partnerships —

Partnerships are a fundamental part of our business.. We work with >300 partners in production, development, portfolio licensing, and commercialization. We cooperate very closely with them and invest significantly to help broaden patient access and to improve health outcomes.

Investors —

Our vision is clear – to be the best specialty and hospital pharma partner in Europe & Canada. In addition, we can leverage our operations centre of excellence and our global network of partnerships to bring our medicines to patients.

We will do this by continuing to expand our business via acquisitions, in-licensing agreements, and launches to drive growth, especially in our focus therapeutic areas as well as more broadly in rare diseases.

Latest News —

Image for ADVANZ PHARMA launches Palmeux®/Paliperidone 1-month long-acting injection across various European countries

Press Releases — 17 Feb 2023

ADVANZ PHARMA launches Palmeux®/Paliperidone 1-month long-acting injection across various European countries

Learn more
Image for ADVANZ PHARMA enters into an exclusive agreement with Alvotech to commercialise a proposed biosimilar to Xolair® (omalizumab)

Press Releases — 06 Feb 2023

ADVANZ PHARMA enters into an exclusive agreement with Alvotech to commercialise a proposed biosimilar to Xolair® (omalizumab)

Learn more
Image for ADVANZ PHARMA to receive exclusive rights from Applied Therapeutics to commercialise AT-007 (govorestat) in Europe

Press Releases — 04 Jan 2023

ADVANZ PHARMA to receive exclusive rights from Applied Therapeutics to commercialise AT-007 (govorestat) in Europe

Learn more
Image for ADVANZ PHARMA further strengthens its specialty and hospital business by acquiring an anti-infective portfolio from Sanofi

Press Releases — 03 Oct 2022

ADVANZ PHARMA further strengthens its specialty and hospital business by acquiring an anti-infective portfolio from Sanofi

Learn more
Image for ADVANZ PHARMA to receive exclusive rights from PolyPid to commercialize D-PLEX100 in Europe

Press Releases — 03 Aug 2022

ADVANZ PHARMA to receive exclusive rights from PolyPid to commercialize D-PLEX100 in Europe

Learn more
Image for ADVANZ PHARMA completes acquisition of Intercept’s business in Europe, Canada, and all other markets outside of the U.S.

Press Releases — 01 Jul 2022

ADVANZ PHARMA completes acquisition of Intercept’s business in Europe, Canada, and all other markets outside of the U.S.

Learn more